Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Trk kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Trk Receptor (43) Akt (1) Apoptosis (7) Autophagy (4) Bcr-Abl (1) c-Fms (1) c-Kit (1) c-Met/HGFR (2) CaMK (1) CDK (2) Drug Metabolite (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) ERK (1) FLT3 (2) PDGFR (1) PKA (1) PKC (1) PROTACs (1) Reference Standards (4) ROS Kinase (1) VEGFR (1)
By Research Areas:	Cancer (43) Infection (1) Inflammation/Immunology (2) Neurological Disease (5)

Inhibitors & Agonists

Natural
Products

Targets Recommended: Trk Receptor

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-12866

Larotrectinib 15+ Cited Publications LOXO-101; ARRY-470	Trk Receptor Apoptosis	Cancer
Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase *(TRK)* family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

HY-N6732

K-252a 25+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	Autophagy PKA PKC Trk Receptor CaMK	Infection Inflammation/Immunology
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-13491

GNF-5837 4 Publications Verification	Trk Receptor	Cancer
GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC₅₀ values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively) .

HY-101977

Selitrectinib 5 Publications Verification LOXO-195	Trk Receptor	Cancer
Selitrectinib (LOXO-195) is a next-generation **TRK kinase inhibitor, with IC₅₀s of 0.6 nM and <2.5 nM for TRKA and TRKC**, respectively .

HY-10424

Milciclib 5+ Cited Publications PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC₅₀s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-148811

Zurletrectinib ICP-723	c-Met/HGFR Trk Receptor	Cancer
Zurletrectinib is a brain-penetrant, orally active *TRK* inhibitor (TRKA IC₅₀ = 0.81 nM; TRKB IC₅₀ = 0.145 nM; TRKC IC₅₀ = 0.184 nM). Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations). Zurletrectinib can be used for the study of glioma .

HY-12866A

Larotrectinib sulfate 15+ Cited Publications LOXO-101 sulfate; ARRY-470 sulfate	Trk Receptor Apoptosis	Cancer
Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase *(TRK)* family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

HY-B0791

Altiratinib 1 Publications Verification DCC-2701	VEGFR c-Met/HGFR FLT3 Trk Receptor	Cancer
Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC₅₀s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, *Trk1, Trk2, and Trk3* respectively.

HY-15590

AZ-23 3 Publications Verification AZD1332	Trk Receptor	Cancer
AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC₅₀s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.

HY-137465

CG428	PROTACs Trk Receptor	Cancer
CG428 is a potent and selective CRBN-dependent tropomyosin receptor kinase (TRK) PROTAC degrader that has anti-tumor activity. CG428 reduces levels of the tropomyosin 3 TPM3-TRKA fusion protein in KM12 colorectal carcinoma cells (DC₅₀ = 0.36 nM) and inhibits downstream PLCγ1 phosphorylation (IC₅₀ = 0.33 nM). CG428 has a higher binding affinity for TRKA than TRKB and TRKC (Kd = 1 nM, 28 nM and 4.2 nM, respectively). CG428 can be used for the research of colorectal carcinoma .

HY-46531

Thalidomide-5-NH2-CH2-COOH	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Inflammation/Immunology Cancer
Thalidomide-5-NH2-CH2-COOH (compound 114) is a potent and selective inhibitor of tropomyosin receptor kinase (trk). Thalidomide-5-NH2-CH2-COOH is a ligand of E3 ligase. Thalidomide-5-NH2-CH2-COOH has the potential for researching one or more diseases (extracted from patent WO2021170109A1) .

HY-122616

PF-06273340	Trk Receptor	Neurological Disease
PF-06273340 is a peripherally restricted pan-Trk inhibitor with IC₅₀ values of 6, 4, 3 nM for TrkA, TrkB, and TrkC receptors. PF-06273340 binds in a DFG-out conformation, targeting less conserved kinase ligand binding domain regions outside the ATP binding pocket. PF-06273340 exhibits anti-hyperalgesic and analgesic effects. PF-06273340 can be used for the research of pain .

HY-146697

IHMT-TRK-284	Trk Receptor c-Fms PDGFR Bcr-Abl c-Kit Apoptosis	Cancer
IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC₅₀ values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies .

HY-177082

Eratrectinib	Trk Receptor	Cancer
Eratrectinib (Example 1) is a *Trk* inhibitor. Eratrectinib can be studied in research for tropomyosin receptor kinase-related diseases and cancers .

HY-161179

TRK-IN-27	Trk Receptor	Cancer
TRK-IN-27 (Compound 14q) is a potent *TRK* inhibitor with good kinase selectivity. TRK-IN-27 effectively inhibits tumor growth .

HY-124637

ALE-0540	Trk Receptor	Neurological Disease
ALE-0540, a nonpeptidic small molecule, is a nerve growth factor receptor antagonist. ALE-0540 inhibits the binding of NGF to tyrosine kinase (Trk) A or both p75 and TrkA with IC₅₀ values of 5.88 μM and 3.72 μM, respectively. ALE-0540 can be used to examine mechanisms leading to the development of agents for the study of pain .

HY-150561

Trk-IN-20	Trk Receptor	Cancer
Trk-IN-20 is a kind of 3-vinylindazole derivatives. Trk-IN-20 suppresses *Trk* kinases functions by phosphorylation inhibition of TrkA/B/C with IC₅₀ values of 1.6 nM, 2.9 nM and 2.0 nM, respectively .

HY-144424

Trk-IN-11	Trk Receptor	Cancer
Trk-IN-11 (Compound 14h) is a potent inhibitor of *TRK* (IC₅₀ = 1.4, 1.8 nM, against TrkA, TrkA ^G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-11 has the potential for the research of cancer disease .

HY-144423

Trk-IN-10	Trk Receptor	Cancer
Trk-IN-10 (Compound 14j) is a potent inhibitor of *TRK* (IC₅₀ = 0.86, 6.92 nM, against TrkA, TrkA ^G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-10 (IC₅₀ = 350 nM against ALK) has a higher selectivity of Trk inhibition, which may be of great significance for reducing toxicity .

HY-12327

Trk-IN-1	Trk Receptor	Neurological Disease Cancer
Trk-IN-1 (example 9), a potent tropomyosin-related kinase (Trk) inhibitor, shows potency against TrkA (3.7 nM) and TrkB (94 nM), respectively .

HY-146521

TRK-IN-15	Trk Receptor	Cancer
TRK-IN-15 is a potent inhibitor of *TRK. Protein kinases* play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-15 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-55) .

HY-146522

TRK-IN-16	Trk Receptor	Cancer
TRK-IN-16 is a potent inhibitor of *TRK. Protein kinases* play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-16 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-21) .

HY-146519

TRK-IN-14	Trk Receptor	Cancer
TRK-IN-14 is a potent inhibitor of *TRK. Protein kinases* play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-14 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-47) .

HY-146518

TRK-IN-13	Trk Receptor	Cancer
TRK-IN-13 is a potent inhibitor of *TRK. Protein kinases* play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-13 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-24) .

HY-146523

TRK-IN-17	Trk Receptor	Cancer
TRK-IN-17 is a potent inhibitor of *TRK. Tropomyosin-related kinases* (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-17 has the potential for the research of cancer diseases (extracted from patent WO2021148807A1, compound 3) .

HY-146524

TRK-IN-18	Trk Receptor	Cancer
TRK-IN-18 is a potent inhibitor of *TRK. Tropomyosin-related kinases* (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2021148805A1, compound 7) .

HY-174330A

TRK-IN-31 hydrochloride	Trk Receptor	Cancer
TRK-IN-31 hydrochloride is an orally active *TRK* inhibitor with an IC₅₀ of 1.8 nM. TRK-IN-31 hydrochloride has superior antiproliferative activity in the Ba/F3-MPRIP-TRKA ^G667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 hydrochloride significantly inhibits tumor growth in Ba/F3-MPRIP-TRKA ^G667C subcutaneous tumor mice model .

HY-174330

TRK-IN-31	Trk Receptor	Cancer
TRK-IN-31 is an orally active *TRK* inhibitor with an IC₅₀ of 1.8 nM. TRK-IN-31 has superior antiproliferative activity in the Ba/F3-MPRIP-TRKA ^G667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 significantly inhibits tumor growth in Ba/F3-MPRIP-TRKA ^G667C subcutaneous tumor mice model .

HY-153745

*Protein kinase* inhibitor 5**	Trk Receptor	Cancer
Protein kinase inhibitor 5 is a potent *TRK-A* inhibitor with an IC₅₀ value of 1.8 nM. Protein kinase inhibitor 5 inhibits cell viability .

HY-153745A

*Protein kinase* inhibitor 5 sulfate hydrate**	Trk Receptor	Cancer
Protein kinase inhibitor 5 sulfate hydrate is a potent *TRK-A* inhibitor with an IC₅₀ value of 1.8 nM. Protein kinase inhibitor 5 sulfate hydrate inhibits cell viability .

HY-153743

*Protein kinase* inhibitor 4**	ROS Kinase Trk Receptor	Cancer
Protein kinase inhibitor 4 (Compound 3) is a protein kinase inhibitor that inhibits *TRK-A* and ROS1 (IC₅₀=3.0 nM and 104 nM respectively) .

HY-147303

Sacibertinib	Trk Receptor EGFR	Cancer
Sacibertinib is a tyrosine kinase (Trk) inhibitor with EC₅₀ value of 110 nM and 244 nM for EGFR-TK phosphorylation and HER2, respectively. Antineoplastic activity .

HY-168858

TRK-IN-30	Trk Receptor	Cancer
TRK-IN-30 (Compound C11) is the inhibitor for tropomyosin receptor kinase (TRK) that inhibits TRKA, TRKB and TRKC and drug resistant mutant TRKA ^G595R with an IC₅₀ of 1.8, 0.98, 3.8, and 54 nM, respectively. TRK-IN-30 inhibits the activation of the downstream PI3K/AKT and MEK/ERK signaling pathways. TRK-IN-30 inhibits the colony formation and cell migration of Km-12, arrests the cell cycle at G0/G1 phase, and induces apoptosis in Km-12 .

HY-120393

GZ-389988	Trk Receptor	Cancer
GZ-389988 is a potent pan-TRK inhibitor with IC₅₀ values of 0.3, 0.1, and 0.5 nM for TRKA, TRKB, and TRKC, respectively. GZ-389988 can be used to study NTRK fusion-positive tumors .

HY-101977R

Selitrectinib (Standard) LOXO-195 (Standard)	Reference Standards Trk Receptor	Cancer
Selitrectinib (Standard) is the analytical standard of Selitrectinib. This product is intended for research and analytical applications. Selitrectinib (LOXO-195) is a next-generation **TRK kinase inhibitor, with IC₅₀s of 0.6 nM and <2.5 nM for TRKA and TRKC**, respectively .

HY-101977B

(3aR)-Selitrectinib (3aR)-LOXO-195	Trk Receptor	Cancer
(3aR)-Selitrectinib ((3aR)-LOXO-195) is an isform of Selitrectinib (HY-101977), which is a next-generation **TRK kinase inhibitor, with IC₅₀s of 0.6 nM and <2.5 nM for TRKA and TRKC**, respectively .

HY-164461

AZD6918	Trk Receptor	Cancer
AZD6918 is an orally active and selective **Trk tyrosine kinase** inhibitor. AZD6918 induces cell death as a single agent and attenuates BDNF/TrkB-induced protection from Etoposide (HY-13629) in vitro. AZD6918 can be used for the research of neuroblastoma .

HY-E70785

TRKA G667C Recombinant Human Active Protein Kinase	Trk Receptor	Cancer
TRKA is a member of the tropomyosin receptor kinase (TRK) family, and its primary binding ligand is nerve growth factor (NGF). TRKA G667C is a mutant of TRKA. TRKA G667C Recombinant Human Active Protein Kinase is a recombinant TRKA G667C protein that can be used to study TRKA G667C-related functions .

HY-12866R

Larotrectinib (Standard) LOXO-101 (Standard); ARRY-470 (Standard)	Reference Standards Trk Receptor Apoptosis	Cancer
Larotrectinib (Standard) is the analytical standard of Larotrectinib. This product is intended for research and analytical applications. Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase *(TRK)* family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

HY-112436A

(3S,4R)-PF-6683324	Trk Receptor	Neurological Disease Cancer
(3S,4R)-PF-6683324 is a tropomyosin-related kinase (Trk) inhibitor extracted from patent WO2015092610A1 example 9. (3S,4R)-PF-6683324 has the potential for the research of pain and cancer .

HY-108263A

(S)-3-Hydroxy Midostaurin (S)-CGP52421	FLT3 Drug Metabolite	Cancer
(S)-3-Hydroxy Midostaurin ((S)-CGP52421) is a potent kinases inhibitor with IC₅₀ values of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et). (S)-3-Hydroxy Midostaurin is a minor metabolite of midostaurin (PKC412; HY-10230) undergoing by the hepatic CYP3A4 enzyme. (S)-3-Hydroxy Midostaurin has the potential for acute myeloid leukemia (AML) .

HY-12866AR

Larotrectinib sulfate (Standard) LOXO-101 sulfate (Standard); ARRY-470 sulfate (Standard)	Trk Receptor Apoptosis Reference Standards	Cancer
Larotrectinib sulfate (Standard) is the analytical standard of Larotrectinib sulfate. This product is intended for research and analytical applications. Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

HY-10424R

Milciclib (Standard) PHA-848125 (Standard)	Reference Standards CDK Autophagy	Cancer
Milciclib (Standard) is the analytical standard of Milciclib. This product is intended for research and analytical applications. Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-146755

TIY-7	Trk Receptor	Cancer
TIY-7 is a selective and orally active tropomyosin receptor kinase (TRK) inhibitor. TIY-7 shows enzyme inhibitory activity with IC₅₀s of 2.9, 1.1, 0.7, 0.8, 0.8, 0.2 nM for TRKA, TRKA ^G595R, TRKA ^G667C, TRKA ^F589L, TRKC ^G623R, TRKC ^G696A, respectively. TIY-7 shows anti-tumor potency in mouse xenograft model .

HY-181780

TRK-IN-34	Trk Receptor	Cancer
TRK-IN-34 is an orally active TRKand TRKC mutant kinase inhibitor, with IC₅₀ values of 0.75 nM and 0.96 nM against TRKA ^G595R and TRKA ^G667C, respectively. TRK-IN-34 inhibits the kinase activities of TRKA ^G595R and TRKA ^G667C at the functional level. TRK-IN-34 inhibits the proliferation of TRKA-transfected cells, exerts tumor growth-inhibitory effects and achieves partial tumor regression in xenograft models. TRK-IN-34 can be used to study TRK inhibitor-resistant cancers driven by the TRKA ^G667C mutation .

HY-12328

Trk-IN-2	Trk Receptor	Neurological Disease
Trk-IN-2 is an orally active *pan-Trk* kinase inhibitor with an TrkA IC₅₀ of 9 nM. Trk-IN-2 exhibits pharmacodynamic effects in rat models of inflammatory pain and neuropathic pain.Trk-IN-2 can be used for the research of inflammatory pain, neuropathic pain .

HY-181871

DZX19	Trk Receptor Akt ERK Apoptosis	Cancer
DZX19 (Compound C02) is an orally active, selective *TRK* inhibitor with a TRKA IC₅₀ value of 1.32 nM, a TRKB IC₅₀ of 2.28 nM, and a TRKC IC₅₀ of 4.05 nM. DZX19 inhibits the kinase activities of wild-type TRKA, TRKA mutants (G595R, F589L, G667C), wild-type TRKB, and wild-type TRKC, and suppresses the phosphorylation of TRKA as well as its downstream AKT and ERK signaling pathways. DZX19 induces apoptosis. DZX19 inhibits tumor growth in a colorectal cancer xenograft mouse model. DZX19 is applicable for the research of colorectal cancer .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

Trk kinases

Inhibitors & Agonists

NaturalProducts

Natural
Products